How should Journavx (suzetrigine) be used with opioids for acute pain management in adults?

Journavx (Suzetrigine) Use with Opioids for Acute Pain Management

Journavx should be used as a first-line non-opioid alternative to opioids for moderate to severe acute pain in adults, with opioids reserved only as rescue medication when pain control is inadequate. 1

Primary Recommendation: Journavx as Opioid-Sparing Agent

Journavx (suzetrigine) is FDA-approved specifically for moderate to severe acute pain in adults and represents the first new class of analgesics in nearly 30 years 1, 2. The drug works by selectively blocking voltage-gated sodium channel 1.8 (NaV1.8) on peripheral pain-sensing nerves, providing analgesia without central nervous system effects or addiction potential 2, 3.

Dosing Strategy

• Starting dose: 100 mg orally on empty stomach (at least 1 hour before or 2 hours after food)
• Maintenance: 50 mg every 12 hours starting 12 hours after initial dose (can be taken with or without food)
• Duration: Use for shortest duration consistent with treatment goals; not studied beyond 14 days 1

Integration with Multimodal Therapy

Journavx should be combined with acetaminophen and NSAIDs as part of multimodal therapy, NOT routinely combined with opioids. This approach aligns with current pain management guidelines that prioritize non-opioid analgesics as first-line treatment 4, 5.

Recent evidence demonstrates that when Journavx is used as part of multimodal therapy (with acetaminophen and ibuprofen), 76.1% of surgical patients required no opioid rescue medication postoperatively 6. Among those who did require opioids, the mean was only 2.2 tablets over 1.7 days 6. This represents a dramatic reduction compared to traditional opioid-based regimens.

When Opioids May Be Added

Reserve opioids strictly as rescue medication only when:

• Pain assessment 2-4 hours after Journavx loading dose shows inadequate relief (numeric pain rating scale remains ≥4)
• Patient reports pain control as poor/fair on global assessment
• Multimodal therapy including Journavx, acetaminophen, and NSAIDs has been optimized

Opioid Selection if Needed

If rescue opioids are required, follow established guidelines 4:

• Use immediate-release formulations only (e.g., oxycodone 5-15 mg or hydrocodone/acetaminophen 5-10/325 mg every 4-6 hours as needed)
• Start with lowest effective dose
• Prescribe for limited duration (≤7 days) 7
• Never use long-acting or extended-release opioids (e.g., OxyContin, MS Contin, fentanyl patches) for acute pain 7

Critical Safety Considerations

Drug Interactions Requiring Dose Adjustment

Contraindicated combinations:

• Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) - absolute contraindication 1
• Grapefruit or grapefruit juice - avoid completely 1

Dose reduction required:

• Moderate CYP3A inhibitors - reduce Journavx dose (specific adjustments in prescribing information) 1

Avoid concurrent use:

• Strong or moderate CYP3A inducers (e.g., rifampin, carbamazepine, phenytoin) - may reduce Journavx efficacy 1

Hepatic Impairment

• Moderate impairment (Child-Pugh B): Reduced dosing required
• Severe impairment (Child-Pugh C): Avoid use 1

Opioid-Specific Warnings

Never co-prescribe opioids with benzodiazepines or other sedative-hypnotics when using Journavx as this dramatically increases overdose risk 8. This is a Level C recommendation from emergency medicine guidelines that applies regardless of the primary analgesic used.

Clinical Algorithm for Pain Management

1. Initiate Journavx with multimodal therapy (acetaminophen + NSAID if not contraindicated)
2. Assess pain at 2-4 hours after loading dose 2
3. If inadequate relief: Add immediate-release opioid as rescue (lowest dose, PRN only)
4. Reassess daily: Most patients (83-91%) rate pain control as good to excellent with Journavx alone 2, 9
5. Discontinue opioids first as pain improves, continue Journavx up to 14 days if needed

Common Pitfalls to Avoid

• Do not routinely prescribe opioids alongside Journavx - this defeats the purpose of opioid-sparing analgesia
• Do not use Journavx beyond 14 days - no safety/efficacy data exists for longer duration 1
• Do not crush or chew tablets - must be swallowed whole 1
• Do not forget the empty stomach requirement for the loading dose - food significantly affects absorption 1
• Do not assume prior authorization is automatic - check insurance coverage before discharge to avoid treatment delays 2

Evidence Quality Note

The recommendation to use Journavx as an opioid-sparing agent is based on FDA approval 1 and recent phase 3 trials showing non-inferiority to hydrocodone/acetaminophen for post-surgical pain 10. The multimodal approach enabling opioid-free recovery is supported by a 2026 phase 4 study 6. This represents the highest quality, most recent evidence available for this newly approved medication.

The broader principle of minimizing opioid use for acute pain is strongly supported by multiple high-quality guidelines 4, 5, 8, which consistently recommend non-opioid analgesics as first-line therapy and opioids only when other options fail.